Navigation Links
BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
Date:5/14/2013

customer was recognized as all future performance obligations associated with the previous license agreements were cancelled with the agreement signed in the first quarter of 2013.

Gross margin as a percentage of revenue decreased to 52.1% in the first quarter of 2013 compared to 58.6% for the same period in 2012 due primarily to the increase in contract manufacturing product sales, which has a higher cost of sales, compared to core product sales, offset by recognition of the license revenue during the quarter with no associated costs.

Operating expenses in the first quarter of 2013 were $0.9 million compared with $0.7 million in the first quarter of 2012. This increase was primarily attributable to additional personnel costs that commenced in the second quarter of 2012, higher corporate costs, higher depreciation and rent costs related to the new facility, and higher office-related expenses.

For the first quarter of 2013, the Company reported operating income of $0.2 million compared to operating loss of $0.2 million in the first quarter of 2012. Net loss was $(7,176), or $(0.00) per share for the first quarter of 2013, compared to a loss of $0.3 million or $(0.00) per share in the first quarter of 2012.

Outlook for 2013The Company continues to expect the following 2013 results:

  • Revenue in the range of $6.5 million to $7.0 million, driven by continued increases in sales to existing core product and contract manufacturing customers, the addition of new customers in the regenerative medicine market as customers continue to move their cell and tissue-based therapies and products through the clinical trial and regulatory approval processes, and continued focus on sales through existing distribution network. The Company does not anticipate additional licensing transactions similar to that concluded in the first quarter.
  • Gross margin as a percentage of revenue of approximately 38% - 41% in 2013, with fluctuation occurring
    '/>"/>

  • SOURCE BioLife Solutions, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
    2. BioLife Solutions 2011 Revenue Up 33%
    3. BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board
    4. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
    5. BioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite
    6. BioLife Solutions Announces 2012 Second Quarter Results: Eighth Straight Quarter of Record Revenue
    7. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
    8. BioLife Solutions Announces 2012 Third Quarter Results: Ninth Straight Quarter of Record Revenue
    9. BioLife Solutions Announces License Agreement
    10. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
    11. ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Vermillion, Inc. (Nasdaq:   VRML), a ... today that investors including Oracle Investment Management, ... several Vermillion directors have agreed to purchase approximately ... stock and warrants to purchase unregistered shares of ... Under the terms of the private ...
    (Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
    (Date:12/24/2014)... and NEW YORK , Dec. 23, ... open-label pilot study of mazindol in children with attention ... Therapy in December 2014 . The ... children with attention deficit/hyperactivity disorder" ( Konofal et al, ... Dec 1;8:2321-2332. eCollection 2014 ) shows that mazindol ...
    (Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
    Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
    ... CITY, China, July 2 /Xinhua-PRNewswire-FirstCall/,-- China Pharma Holdings, ... manufactures, and markets generic and branded bio-,pharmaceutical products ... at the Collins Stewart Fourth Annual Growth Conference ... conference is being held at the Mandarin,Oriental Hotel ...
    ... cells manufactured from bone marrow; SV ... SALT LAKE CITY and HAMBURG, Germany, July 2 ... cell therapies,for the treatment of acute kidney injury, today ... round was led by SV Life Sciences with Novo,A/S ...
    ... MELBOURNE, Australia, July 2 Research conducted ... has contributed significantly to a,major licensing agreement ... Germany-based pharmaceutical company, Merck,Serono., Under the ... seek,to develop new treatments for multiple sclerosis ...
    Cached Biology Technology:China Pharma Holdings, Inc. to Present at Collins Stewart Fourth Annual Growth Conference in New York on July 8, 2008 at 2:00 p.m. EDT 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 3MS Drug Development Agreement Based on WEHI's Medicinal Chemistry 2
    (Date:12/17/2014)... , Dec. 16, 2014 Research and ... the addition of the "Global Chemical Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the increasing demand for medical sensors in biomedical ... data for quick and correct diagnosis during surgical ...
    (Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
    (Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
    Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
    ... as part of her undergraduate degree (MSci in Palaeontology and ... evolved in a most unusual way, becoming more and more ... is published today in the Journal of Systematic Palaeontology ... plants evolves, they quickly try out all the options. ...
    ... the Georgia Institute of Technology have designed a multiple-compartment ... drugs of different types. The researchers used a simple ... less than one micron. The capsule,s structure -- ... of the shell -- provides spatially-segregated compartments that make ...
    ... mapping various genomes onto an X-Y axis, a team comprised ... Darwin and a fruit fly -- among other organisms -- ... Size in Diploid Eukaryotic Species Centers on the Average Length ... Molecular Biology and Evolution . It details a project ...
    Cached Biology News:The rise and rise of the flying reptiles 2Unique gel capsule structure enables co-delivery of different types of drugs 2Discovering the bigger picture in chromosomes 2Discovering the bigger picture in chromosomes 3
    ... Proliferator-Activated Receptor-gamma (PPAR) is a member ... ligand-activated transcription factors that heterodimerize with ... involved in the regulation of glucose ... (TZD) class of anti-diabetic agents called ...
    ... Service includes 1. Scanning of gel(s) ... High-sensitive tryptic in-gel digestion and peptide ... MALDI-MS 5. Acquisition of PMF (Peptide ... ultraflex TOF/TOF) 6. Acquisition of PFF ...
    ... Preparation Reconstitution: one vial contains ... ficoll and 50 mg PVP; ... water yields a 50concentrate Special ... 1.00 g/mL (20 C) Quality ...
    ... ImageXpress 5000A automated cellular imaging and analysis ... system designed specifically for rapid acquisition and ... cell-based screening. ImageXpress is fast. Scanning ... (1280 x 1024 pixels), with two fluorescence ...
    Biology Products: